XGN Exagen

Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025

Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025

CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the market opens on Tuesday, November 4, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT).

Conference Call & Webcast:

  • U.S. dial-in: 201-389-0918
  • International dial-in: 877-407-0890
  • Webcast: Available via the Exagen investor relations website at



Replay: A telephone replay will be available until Tuesday, November 18, 2025:

  • U.S. replay: 201-612-7415
  • International replay: 877-660-6853
  • Replay passcode: 13756599
  • Webcast: A recoding of the webcast will be available one hour after the call concludes via the Exagen investor relations website at



About Exagen Inc.

Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease earlier and with greater accuracy. Exagen’s CLIA-certified, CAP-accredited laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.

For more information, visit or follow Exagen on .

Contact:

Ryan Douglas

Exagen Inc.



760.560.1525



EN
21/10/2025

Underlying

XGNExagen

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Exagen

 PRESS RELEASE
Free
XGN EXAGEN

Exagen Announces Acceptance of Six Abstracts at 2025 American College ...

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2025, being held October 24-29, 2025, at the McCormick Place Convention Center in Chicago, Illinois. Exagen’s featured plenary presentation, in collaboration with Johns Hopkins University, will highlight a urinary biomarker panel that holds t...

October 23, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. to Announce Third Quarter 2025 Financial Results on Novemb...

Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the market opens on Tuesday, November 4, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast: U.S. dial-in: 201-389-0918Intern...

October 21, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. to Participate in Third Quarter Investor Conferences

Exagen Inc. to Participate in Third Quarter Investor Conferences CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity 45th Annual Growth Conference Participation: Fireside Chat and 1X1 Meetings Date: Tuesday, August 12, 2025 Location: InterContinental Hotel in Boston, MA Cantor Global Healthcare Conference 2025 Participation: Fireside Chat and 1X1 Meetings Date: W...

August 6, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. Reports Strong Q2 2025 Results

Exagen Inc. Reports Strong Q2 2025 Results CARLSBAD, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2025, and recent corporate updates.   Three Months Ended June 30, Six Months Ended June 30,   2025   2024   2025   2024 (Unaudited, in thousands, exceptASP data)  Revenue $17,202  $15,064  $32,700  $29,479 Gross margin  60.4%  60.1%  59.7%  59.9%Operating expenses $13,025  $11,643  $25,513  $23,244 Operating loss $(2,630)  $(2,587)  $(5,995)  $(5,590) Net...

July 29, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. Appoints Chas McKhann to Board of Directors

Exagen Inc. Appoints Chas McKhann to Board of Directors CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions leading turnaround and transformational growth at multiple medical technology companies. Most recently, Mr. McKhann served as Board member, President and ...

July 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch